Understanding these compensatory mechanisms could inform strategies to disrupt tumor metabolism by targeting NETs and ROS, potentially leading to more effective and resistance-free therapeutic outcomes.Future research should explore the compensatory relationships and between metabolic pathways, focusing on key regulators like HIF-1α and ROS. This evidence concerns the gene HIF1A and neoplasm.